Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation.

abstract：:Congestive heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with more than 290 000 deaths in the United States each year. Recent advances in heart failure therapy target many of the mechanical and structural aspects of heart failure...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Thompson KA,Philip KJ,Barbagelata A,Schwarz ER

更新日期：2010-06-01 00:00:00

abstract：:The peptide hormone relaxin has traditionally been linked to the maternal adaptation of the cardiovascular system during the first trimester of pregnancy. By promoting nitric oxide formation through different molecular signaling events, relaxin has been proposed as a pleiotropic and cardioprotective hormone in the set...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Raleigh JM,Toldo S,Das A,Abbate A,Salloum FN

更新日期：2016-07-01 00:00:00

abstract：:Prior studies have suggested that intravenous diltiazem reduces the probability of spontaneous conversion of atrial fibrillation (AF) to sinus rhythm in the electrophysiology laboratory and in patients with postoperative AF. Whether diltiazem exerts the same effect in patients presenting to the emergency department (E...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hassan S,Slim AM,Kamalakannan D,Khoury R,Kakish E,Maria V,Ahmed S,Pires LA,Kronick SL,Oral H,Morady F

更新日期：2007-09-01 00:00:00

abstract：:Atrial fibrillation has recently come into clinical and research focus. In particular, ventricular rate control has been carefully compared with atrial rhythm control. Additionally, the recent discovery of atrial stunning has initiated clinical and research interest in atrial remodeling. Atrial fibrillation is more li...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Opie LH

更新日期：2003-06-01 00:00:00

abstract：:Antiplatelet therapy is indicated for the treatment of ischemic stroke or transient ischemic attack (TIA). Aspirin reduces subsequent occlusive vascular events, including recurrent stroke, by about 25%. In such patients, clopidogrel has been evaluated in an effort to further reduce risk. In the Management of Atherothr...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gorelick P,Sechenova O,Hennekens CH

更新日期：2006-12-01 00:00:00

abstract：:Approximately 40% of heart attack survivors remain at increased risk of recurrent cardiovascular events, despite the current treatment options showing that atherothrombosis is not exclusively a disorder of lipoprotein aggregation in the arterial wall. Clinical and experimental data suggest that inflammation plays an i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kottoor SJ,Arora RR

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Insulin resistance (IR) is a well-known risk factor for cardiovascular complications. This study aimed to investigate the effect of a dietary model of IR in mice on cardiac remodeling, cardiac β-arrestin2 signaling, and the protective effects of carvedilol as a β-arrestin-biased agonist. METHODS AND RESULTS...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ibrahim WS,Ibrahim IAAE,Mahmoud MF,Mahmoud AAA

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:We hypothesized that the cardioprotective effect of angiotensin II (AngII) type 1 receptor (AT(1)R) blockade during in vivo ischemia-reperfusion (IR) might be associated with an increase in AngII type 2 receptor (AT(2)R) protein, as well as 1,4,5-inositol trisphosphate type 2 receptor (IP(3)R) and protein ki...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Jugdutt BI,Xu Y,Balghith M,Moudgil R,Menon V

更新日期：2000-10-01 00:00:00

abstract：BACKGROUND:Allogeneic cardiosphere-derived cells (CDCs) exert cardioprotective effects when administered intracoronarily after reperfusion in animal models of acute myocardial infarction (AMI). The "no-reflow" phenomenon develops rapidly post-reperfusion and may undermine the efficacy of cell therapy, due to poor cell ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sousonis V,Sfakianaki T,Ntalianis A,Nanas I,Kontogiannis C,Aravantinos D,Kapelios C,Katsaros L,Nana M,Sampaziotis D,Sanoudou D,Papalois A,Malliaras K

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND:The administration of aspirin is traditionally discontinued prior to coronary artery bypass grafting (CABG), given a potential risk of excessive postoperative bleeding. Few studies have previously suggested the benefits of continuing aspirin until the time of surgery. The primary aim of this review is to eva...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ma X,Ma C,Yun Y,Zhang Q,Zheng X

更新日期：2014-01-01 00:00:00

abstract：:Nonvalvular atrial fibrillation (AF) confers an increased risk of thromboembolism, with a 5-fold higher risk of ischemic stroke. Oral anticoagulation (OAC) has shown to be highly effective in preventing stroke and mortality compared to placebo and is also used in patients without AF for both treatment and prophylaxis ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gallego P,Roldán V,Lip GY

更新日期：2014-01-01 00:00:00

abstract：OBJECTIVE:To investigate the effect of a pharmacist care program on cardiovascular risks in type 2 diabetic patients. METHODS:A 9-month, prospective, randomized, controlled study was conducted in a public hospital in Hong Kong. Patients in the intervention group had regular drug-counseling sessions with pharmacists in...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Chan CW,Siu SC,Wong CK,Lee VW

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Fluvastatin is an inhibitor of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, effectively lowering serum cholesterol concentrations. A high-performance liquid chromatography (HPLC) assay was developed that determined the pharmacokinetics of fluvastatin in healthy individuals after administrat...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Siekmeier R,Lattke P,Mix C,Park JW,Jaross W

更新日期：2001-04-01 00:00:00

abstract：BACKGROUND:Myocardial infarction causes the acidification of the cellular environment and the resultant acidosis maybe arrhythmogenic. The effect of acidosis on the action of antiarrhythmic drugs, an important issue in the antiarrhythmic drug therapy after myocardial infarction, remains to be studied. METHODS:To evalu...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lin C,Ke X,Cvetanovic I,Ranade V,Somberg J

更新日期：2005-03-01 00:00:00

abstract：:Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of beta 1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chron...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Vittorio TJ,Zolty R,Kasper ME,Khandwalla RM,Hirsh DS,Tseng CH,Jorde UP,Ahuja K

更新日期：2008-03-01 00:00:00

abstract：:Low-molecular-weight heparins (LMWHs) endure as important drugs for thromboprophylaxis. Although clinical use relies on the subcutaneous (SC) route, our previous studies show that single-dose orally administered LMWHs have antithrombotic activity. Since thromboprophylaxis requires long-term treatment, we examined anti...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Hiebert LM

更新日期：2017-05-01 00:00:00

abstract：:Postischemic accumulation of intracellular Na+ promotes calcium overload and contributes to cellular necrosis. Cardioprotection afforded by pharmacologic blockade of the sodium-hydrogen exchanger subtype 1 (NHE1) is thought to be more remarkable than that obtained by ischemic conditioning (IC). The window of protectio...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kingma JG

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:Intimal hyperplasia following percutaneous interventional vascular procedures is a major cause of restenosis. Although heparin inhibits intimal hyperplasia, it has not proven clinically useful in part due to an inadequate duration of intramural drug residence. This study was designed to evaluate the efficacy...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sasseen BM,Gray BD,Gal D,Lorinc R,Carpenter DC,Klugherz BD,Wilensky RL

更新日期：2001-10-01 00:00:00

abstract：:We evaluated whether carotenoid astaxanthin (ASX) could prevent oxidative and atherosclerotic damage in rabbits. Rabbits received regular chow (control) or an atherogenic diet (1% cholesterol) alone or supplemented with 50, 100, and 500 mg% ASX for 60 days (n = 5-9 per group). The atherogenic diet increased the serum ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Augusti PR,Conterato GM,Somacal S,Sobieski R,Quatrin A,Maurer L,Rocha MP,Denardin IT,Emanuelli T

更新日期：2009-12-01 00:00:00

abstract：:Cardio-Oncology has blossomed as a new field in cardiovascular medicine, in large part due to new therapies, which may have cardiovascular sequelae. Despite this, anthracyclines still serve as cornerstone therapy for most pediatric cancers, several solid tumors and hematological malignancies. Cardiotoxicity is the mai...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Screever EM,Meijers WC,Moslehi JJ

更新日期：2021-03-01 00:00:00

abstract：:The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes generally become appar...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Novela C,Hennekens CH

更新日期：2004-03-01 00:00:00

abstract：:Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wolbrette DL,Hussain S,Maraj I,Naccarelli GV

更新日期：2019-01-01 00:00:00

abstract：:The aim of this study was to demonstrate whether HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides), was effective in improving levels of plasma free radicals (PFRs) in patients with chronic venous insufficiency (CVI) and venous microangiopathy. Patients were randomized into the treatment group, which received o...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Cesarone MR,Incandela L,DeSanctis MT,Belcaro G,Dugall M,Acerbi G

更新日期：2002-01-01 00:00:00

abstract：:BACKGROUND: Conventional microelectrode techniques were used to compare the concentration-dependent effects of vesnarinone (0.1-100 µM) and amrinone (1 µM-1 mM) on action potential duration (APD) and developed force in both isolated dog ventricular trabeculae and Purkinje strands. METHODS AND RESULTS: Both drugs incre...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lathrop DA,Nánási PP,Varró A,Schwartz A

更新日期：1996-04-01 00:00:00

abstract：BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Varagic J,Susic D,Slama M,Frohlich ED

更新日期：2003-06-01 00:00:00

abstract：:The primary effect of ischemia is reduced aerobic adenosine triphosphate (ATP) formation in mitochondria. This triggers accelerated glycolysis and reduced cell pH, Ca(2+) accumulation, K(+) efflux, adenosine formation, and the clinical signs of ischemia: chest pain and a shift in the ST segment. Traditional therapies ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Stanley WC

更新日期：2004-09-01 00:00:00

abstract：BACKGROUND:Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether the...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Pesaro AE,Serrano CV Jr,Katz M,Marti L,Fernandes JL,Parra PR,Campos AH

更新日期：2013-09-01 00:00:00

abstract：:Homing of cardiac myosin-specific CD4-positive T cells into the myocardium is the initial pathologic event of experimental autoimmune myocarditis (EAM). Subsequently, various bystander inflammatory cells are recruited into the myocardium crossing vascular endothelial cell walls. Sulfated polysaccharide fucoidan binds ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Tanaka K,Ito M,Kodama M,Tomita M,Kimura S,Hoyano M,Mitsuma W,Hirono S,Hanawa H,Aizawa Y

更新日期：2011-03-01 00:00:00

abstract：:Dronedarone is a new antiarrhythmic drug for patients with nonpermanent atrial fibrillation (AF). A relatively consistent finding in all trials studying dronedarone was a moderate but significant elevation of serum creatinine. Since dronedarone competes for the same organic cation transporter in the distal renal tubul...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Duncker D,Oswald H,Gardiwal A,Lüsebrink U,König T,Schreyer H,Klein G

更新日期：2013-03-01 00:00:00

abstract：:Beta-Adrenergic blockers have a wide spectrum of action for controlling cardiac arrhythmias that is larger than initially thought. Data from the past several decades indicate that, as an antiarrhythmic class, beta-blockers remain among the very few pharmacologic agents that reduce the incidence of sudden cardiac death...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh BN

更新日期：2005-06-01 00:00:00